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Abstract
Background/Aim. Inflammation due to infection could be
associated with the development of acute coronary syn-
dromes, clinical manifestations of ongoing atherosclerosis in
vessel walls. Our aim was determine whether interleukin 6,
C-reactive protein and Chlamydia pneumoniae IgG antibodies
are connected with the development of acute coronary syn-
dromes, to evaluate their interrelationship and to examine
whether they are predictive of new events and mortality.
Methods. This prospective study included 211 subjects, of
whom 111 were patients with acute coronary syndromes
(60% male, mean age 59.42 years) and 100 were healthy
controls (58% male, mean age 59.03 yuears). Blood samples
were taken for analysis on admission, before the application
of the therapy. Interleukin 6, high sensitivity C-reactive
protein and Chlamydia pneumoniae IgG antibodies were meas-
ured, in a follow-up period of 30 days. Results. Levels of
interleukin 6 (p < 0.001) and C-reactive protein (p < 0.001)
were significantly higher among the patients with acute
coronary syndromes than among controls. Chronic infec-
tion caused by Chlamydia pneumoniae was present in 72% of
patients and in 22% of healthy controls (p < 0.001). There
was a correlation between interleukin 6 and C-reactive pro-
tein, C-reactive protein and Chlamydia pneumoniae but not
between Chlamydia pneumoniae and interleukin 6. Higher lev-
els of interleukin 6 and C-reactive protein were seen with
increasing body mass index, smoking exposure, presence of
hypertension and diabetes, and decreasing ejection fraction.
The patients with ST-segment elevation had higher exam-
ined markers than the patients without ST-segment eleva-
tion. Interleukin 6 and C-reactive protein were independ-
ently related to the clinical outcome. Conclusion. Interleu-
kin 6, C-reactive protein and Chlamydia pneumoniae infection
are connected with the development of acute coronary syn-
dromes and may reflect a clinical outcome of the disease.
Key words:
coronary disease; inflammation mediators; interleukin-
6; c-reactive protein; chlamydophilia pneumoniae;
prognosis.
Apstrakt
Uvod/Cilj. Inflamacija predstavlja patofiziološki mehani-
zam udružen sa nastankom akutnih koronarnih sindroma
− kliničkih manifestacija uznapredovale arterioskleroze.
Cilj ovog rada bio je ispitivanje povezanosti interleukina
6, C reaktivnog proteina i Chlamydiae pneumoniae sa nastan-
kom akutnih koronarnih sindroma, njihovog međusobnog
odnosa i odnosa sa tradicionalnim faktorima rizika, kao i
prediktivne uloge u nastanku novih događaja i letalnog is-
hoda. Metode Prospektivnom studijom bilo je obuhvaće-
no 211 ispitanika: 111 bolesnika sa akutnim koronarnim
sindromom i 100 zdravih osoba (kontrolna grupa). Uzorci
krvi izvađeni su na prijemu, pre primene terapije. Određi-
vane su vrednosti interleukina 6, visoko osetljivog C rea-
ktivnog proteina i titar antitela klase imunoglobulin G
protiv Chlamydiae pneumoniae. Period praćenja iznosio je 30
dana.  Rezultati.  Interleukin 6 (p < 0,001) i  C  reaktivni
protein (p < 0,001) bili su značajno viši kod osoba obole-
lih od akutnih koronarnih sindroma u odnosu na pripad-
nike kontrolne grupe. Hronična infekcija koja je uzroko-
vana Chlamydiom pneumoniae utvrđena je kod 77% bolesni-
ka i 22% zdravih osoba (p < 0,001). Utvrđena je  korela-
cija između interleukina 6 i C reaktivnog proteina, zatim C
reaktivnog proteina i antitela protiv Chlamydiae pneumoniae.
Porast vrednosti interleukina 6 i C reaktivnog proteina
pratio je porast indeksa telesne mase, pušenje cigareta,
prisustvo hipertenzije i dijabetesa, smanjenje ejekcione
frakcije komora. Ispitivani markeri bili su značajno viši
kod bolesnika sa elevacijom ST segmenta. Oba markera
bila su prediktori novog događaja u periodu praćenja. Za-
ključak. Interleukin 6, C reaktivni protein i infekcija iza-
zvana  Chlamydiom pneumoniae povezani su sa nastankom
akutnih koronarnih sindroma i mogu uticati na klinički is-
hod oboljenja.
Ključne reči:
koronarna bolest; zapaljenje, medijatori; interleukin-6;
c-reaktivni protein; chlamydophylia pneumoniae;
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Introduction
Many molecular and cellular mechanisms link inflam-
mation and haemostatic mechanisms in atherothrombosis,
from the initiation to the clinical manifestation of the process 
1.
Inflammation may promote thrombosis by acting both
locally and systemically. It can affect systemic haemostatic
activity by interleukin-6 (IL-6), the major cytokine responsible
for the acute phase response. High sensitivity testing for C-
reactive protein (CRP), a nonspecific marker of low grade in-
flammation, has received much attention. Several studies
showed a strong link between elevation of CRP and the risk of
future events. Other acute phase proteins, such as leucocytes
count and various proteins concentration (fibrinogen, von
Willebrand factor etc.) also have prognostic significance
 2−6.
Recently, it has been hypothesized that various infective
diseases, both bacterial and viral, may activate vessel associated
leucocytes or immune reactions in arteriosclerotic process.
On the other hand, acute infections can alter haemody-
namics and the clotting and fibrinolytic systems in ways that
can precipitate ischemic events. Chronic extravascular infec-
tions can augment extravascular production of inflammatory
cytokines that may accelerate the evolution of remote arte-
riosclerotic lesions. Intravascular infection might also pro-
vide local inflammatory stimuli that accelerate atherogenesis.
Many human plaques show signs of infection by microbial
agents such as Chlamydia pneumoniae (Cp) which can re-
lease heat shock proteins and stimulate the production of
proinflammatory mediators by vascular endothelial and
smooth muscle cells and infiltrating leucocytes
 7−9.
All of the mentioned components involved in arterioscle-
rotic process are well studied in apparently healthy subjects.
The aim of the study was to investigate the relationship
between levels of IL-6 and CRP and the development of
acute coronary syndromes (ACS). Also, among the other
widely investigated infectious agents, the aim was to deter-
mine the previous exposure to Cp infection in our patient
population by measuring the titers of specific antibodies;
possible interrelationship between examined markers, corre-
lations with risk factors and clinical characteristics and their
prognostic impact.
Methods
The prospective study included 211 participants of
whom 111 were the patients admitted to Coronary Care Unit
(CCU) of Clinic for Cardiovascular Diseases, Clinical Center
Nis in Serbia between December 2002 and May 2004 due to
acute coronary syndromes (ACS) documented by typical
electrocardiographic (ECG) findings for myocardial ische-
mia (T − wave and ST − segment changes) and elevation of
sensitive and specific biomarkers (troponin I and CK − MB).
Examination of patients included data about character-
istic chest pain. The ECG findings were recorded (initial ST
elevation, ST depression, T-wave inversion or nonspecific
changes). Patients were monitored continuously in the CCU.
All traditional risk factors for coronary artery disease (CAD)
were marked: smoking, hypertension, dyslipidemia, diabetes,
body mass index (BMI), family history of CAD. We noted
previous myocardial infarction (MI) or previous coronary
artery by pass grafting (CABG).
The patients required full medical therapy including
various combinations of aspirin, intravenous nitrates, antico-
agulants, angiotensin – converting enzyme inhibitors
(ACEI), statins and/or β-blockers. Where needed, reperfu-
sion was done by using the fibrinolytic agents. We evaluated
the in hospital outcome and end-points in the follow-up pe-
riod of 30 days. All the patients who entered the study were
interviewed by phone. Follow-up information was obtained
about cardiac death, MI or new onset of unstable angina.
Healthy volunteers, a total of 100 persons, composed
the control group. The group was age and sex matched. The
inclusion criteria for the control group were the absence of
known coronary artery diseases (previous stable or unstable
angina as well as previous myocardial infarction) or CAD.
Initial ECG was recorded to confirm the absence of coronary
artery disease. Volunteers were asked about the risk factors
for CAD (smoking status, family history of CAD, hyperten-
sion, dyslipidemia, diabetes) and BMI was determined.
The exclusion criteria in the group of patients and also
of controls were concomitant dilated cardiomyopathy, val-
vular heart disease, atrial fibrillation, major surgery or
trauma within the previous months. All the patients and con-
trols with known or suspected thrombotic disorders, systemic
illness, autoimmune diseases, sepsis, alcohol liver diseases,
chronic obstructive pulmonary diseases, acute respiratory in-
fections, current infections, any etiology or infections within
previous three weeks, malignancy and inflammatory diseases
were also excluded.
The investigation conformed to the principles outlined
in the Declaration of Helsinki. Signed informed consent or
witnessed oral informed consent was obtained from all pa-
tients and healthy controls in accordance with the guidelines
of the Ethical Review Committee of the School Medicine
Nis, University of Nis and Clinical Center of Nis which had
given a written approval of the study.
Blood was drawn from the patients with ACS immedi-
ately after admission, before the application of any therapy.
Regular laboratory analyses were performed in our Central
Laboratory by using standard methods (white blood cell −
WBC counts: reference range 4.5 to 9.0 × 10
9/L and mono-
cytes: reference range 0.0 – 0.8 × 10
9/L). For further analyses
which were not possible to perform in Clinical Center in Nis,
10 ml of serum (patients and controls) were frozen and kept at
– 40 °C. Tubes were sent on dry ice with special permission of
Ministry of Health of Serbia to Immunosciences Lab. Inc,
Beverly Hills, California, USA where the analyses were per-
formed between May and October 2004. We measured the
levels of IL-6, high sensitive − hs CRP and Cp IgG antibodies.
Levels of IL-6 and hs CRP were measured using kits
manufactured by Diagnostic Products Corporation, Los Ange-
les, CA on an IMMULITE Automated Immunoassay Analyzer.
The IMMULITE system utilizes assay-specific, anti-
body or antigen coated plastic beads as the solid phase, alka-
line phosphatase labeled reagent and a chemiliniscent sub-
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The IMMULITE system automates the entire assay
process. Light emission was measured by a photomultiplier
tube and the results were calculated for each sample using
different calibrators and controls.
The established reference ranges of the lab performing
the tests were from 0.7 to 4.6 pg/mL for IL-6, and from 0 to
1 mg/dL for hs CRP. The values higher than the established
reference ranges were marked as positive.
Sera were tested at 1:200 dilution for Cp IgG antibodies
by using an in-house enzyme-linked immunosorbent assay
(ELISA).
Peptide LPTAVLNLTAWNPSLLNATALST from ma-
jor outer membrane protein of Cp was synthesized by Bio-
Synthesis, Louisville, TX, and used in this assay.
Enzyme-linked immunosorbent assay (ELISA) was used
for testing antibodies against nine different specific antigens,
peptides in the sera of the patients with atherothrombosis and
control subjects. Antigens or peptides were dissolved in metha-
nol at a concentration of 1.0 mg/ml, and then diluted 1:100 in
0.1 M carbonate bicarbonate buffer, pH 9.5, and 50 µl were
added to each well of a polystyrene flat-bottom ELISA plate.
Plates were incubated overnight at 4°C and then washed three
times with 20 mM tris buffer saline (TBS) containing 0.05%
Tween 20, pH 7.4. The nonspecific binding of immunoglobulin
was prevented by adding a mixture of 1.5% bovine serum al-
bumin (BSA) and 1.5% gelatin in TBS, and then by incubating
for 2 h at room temperature, and then overnight at 4 °C. Plates
were washed as in the above, and then serum samples diluted
1:200 in 1% BSATBS were added to duplicate wells and incu-
bated for 2 h at room temperature. Sera from patients with
Chlamydia infection with known high titers of IgG against dif-
ferent Cp antigens were used to rule out nonspecific antibody
activities of inter- and intra-assay variability. Plates were
washed, and then peroxidase-conjugated goat antihuman IgG
antiserum (KPI, Gaithersburg, Maryland) diluted 1:400 in 1%
BSA-TBS was added to each well; the plate was incubated for
an additional 2 h at room temperature. After washing five times
with TBS-Tween buffer, the enzyme reaction was started by
adding 100 µl of ophenylene diamine in citrate-phosphate
buffer, pH 5.0 and hydrogen peroxide diluted 1:10,000. After
45 min, the reaction was stopped with 50 µl of 2 N H2SO4.
The optical density (O.D.) was read at 492 nm by means of a
microtitre reader. Several control wells containing all reagents,
but human serum, were used for detecting nonspecific binding.
The curve was constructed by plotting the mean ab-
sorbance obtained from each calibrator against its concentra-
tion with absorbance on the vertical (y) axis, and concentra-
tion on the horizontal (x) axis. By using the mean absorbance
value for each control and unknown samples corresponding
concentration were determined. The test validation, calibra-
tors and control sera were run for each test. The performance
characteristics of this test were determined by using the se-
rum samples; at 3 S.D. above the negative control, samples
were considered positive.
The results of normally distributed continuous variables
are expressed as the mean value ± standard deviation. Con-
tinuous variables with a nonnormal distribution are presented
as median values (interquartile interval) and qualitative vari-
ables are presented as frequencies. Analysis of normality of
the continuous variables was preformed with the Kol-
mogorov–Smirnov test. Differences between the examined
groups were assessed by unpaired t–test, Mann–Whitney U
test and χ
2 testing was used for discrete variables.
Correlations between continuous variables were ana-
lyzed with two-way Pearson correlation tests. Logistic re-
gression was used to assess the univariate associations. In-
formation regarding the development of combined end-point
was available in all the patients included in the study. Binary
logistic regression, backward stepwise selection, was used to
derive final model of which significance levels of 0.01 and
0.05 were chosen to exclude and include terms, respectively.
The relationship between hs CRP levels and the end
point was not of linear nature. Therefore, in order to fulfill
the statistical requirement, hs CRP was logarithmically trans-
formed before entering the multiple regression analysis. Dif-
ferences were considered to be significantly important if the
null hypothesis could be rejected with > 95% confidence. All
p values were two-tailed. The SPSS 10.0 statistical software
package was used for all calculations.
Results
Characteristics of 111 patients with ACS and 100 con-
trols are shown in Table 1.
Table 1
Characteristics of examined groups
Characteristics Patients (n=111) Controls (n=100) p
Age (years), x±SD
Male sex [n(%)]
Current or ex- smokers, [n(%)]
Dyslipidemia (%)
Hypertension (%)
Diabetes (%)
Family history of Coronary artery diseases (%)
Body masa index (kg/m
2), x±SD
Total cholesterol (mmol/L), x±SD
Triglycerides (mmol/L), x±SD
White blood cell count (×10
9/L), x±SD
Monocytes (×10
9/ L), median (range)
59.42±5.4
67 (60.3)
72 (64.8)
47 (42.3)
67 (60.3)
29 (26.1)
67 (60.3)
26.98±2.01
6.03±1.34
2.26±1.53
10.76±2.48
0.9 (0.7–1.22)
59.03±3.56
58 (58)
60 (60)
3 (3)
30 (30)
0 (0)
30 (30)
24.88 (1.48)
4.82 (0.50)
1.35 (0.3)
6.68 (1.04)
0.5 (0.3–0.7)
0.63
0.72
0.46
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
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The majority of the study participants were male
(60.3% of the patients). The mean age of the patients was
59.42 and of controls 59.03 (p = 0.63). A high proportion
of patients, but also of controls were smokers (p = 0.46).
We found elevated white blood cells count (WBC) in pa-
tients with ACS (p < 0.001). Also, monocytes were sig-
nificantly higher in patients than in the controls
(p < 0.001).
Table 2 outlines clinical characteristics of patients with
ACS. Out of 111 patients involved in the study, the present-
ing ECG showed ST − segment elevation in 50 patients. The
mean value of systolic blood pressure was 132±35.98
mmHg. The patients spent in the hospital a period of
10.8±5.4 days to fulfill medical treatment. Previous MI was
recorded in 33 patients and previous CABG in 19 (17.1%).
Aspirin had been used before hospital admission by 38
(34.2%) patients. Fibrinolytic therapy (chiefly streptokinase)
had been received by 44 (39.6%) patients. During the hospi-
tal stay 106 patients received aspirin and 106 received anti-
coagulant therapy (chiefly low molecular weight heparin).
Intravenous nitrates had been received by 105 patients, β-
blockers by 97, ACEI by 72 and statins by 60 of them.  Five
patients had persistent sinus bradycardia, which required
atrial pacing. In our group of patients echo was performed on
89.2% of the patients.
During follow-up, 44 patients had a new event (death,
new MI: reinfarction or MI after unstable angina, or new epi-
sodes of UA). For the primary composite outcome of death, 13
(11.7%) patients died during the first 48 hours in the hospital.
Causes of death are shown in Table 2.
  Our study showed that 46% of the patients had detectable
levels of circulating IL-6 (Figure 1). This proportion is statisti-
cally significantly higher as compared to the controls (only 2%
positive samples), (χ
2 test, p < 0.001; odds ratio (OR), 41.57;
Table 2
Clinical characteristics of patients with acute coronary syndromes (ACS)
Characteristics of patients with ACS  (n = 111) ґ±SD n (%)
Electrocardiography abnormalities at entry
ST-segment elevation
without ST-segment elevation
Systolic blood perasure (BP) (mmHg )
< 120
120−139
140−159
≥ 160
Mean systolic BP (mmHg)
Mean diastolic BP (mmHg)
Heart rate (heartbeats/min)
< 70
70−89
90−109
≥ 110
Mean heart rate (heartbeats/min)
Previous disease and drug use
previous myocardial infarction
previous coronary artery by pass grafting
aspirin before admission
Duration of staying in hospital (days)
Treatment during hospital stay
fibrinolytic agents
aspirin
ticlopidin
anticoagulant
β blocker
angiotensin converting enzyme inhibitors
nitrate (intravenous)
antiarrhythmics
statins
Left ventricle ejection fraction (%)
Left ventricle ejection fraction < 40
New event
Death, any cause
arrhythmia
cardiac rupture
cardiogenic shock
reinfarction
132±35.98
79±23.33
85±22.73
10.8±5.4
54.4±13.30
50 (45)
61 (55)
36 (32.4)
24 (21.6)
17 (15.4)
34 (30.6)
18 (16.3)
43 (38.7)
41 (36.9)
9 (8.1)
33(29.7)
19 (17.1)
38 (34.2)
44 (39.6)
106 (95.4)
7 (6.3)
106 (95.4)
97 (87.3)
72 (64.8)
105 (94.5)
32 (28.8)
60 (54)
16 (14.4)
44 (39.6)
13 (11.7)
4 (3.6)
1 (0.9)
5 (4.5)
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(95% CI, 9.38 − 258.94). Concentrations of IL-6 were signifi-
cantly higher in patients compared to controls (4.7 pg/mL (4.00
– 8.85) vs 1.5 pg/mL (1.2 − 1.8), p < 0.001) (Figure 2-A).
Fig. 1 − Percentage of interleukin 6 (IL–6), C-reactive protein
(CRP) and Chlamydia pneumoniae (Cp) IgG in the examined
groups
Fig. 2 − Comparison of interleukin 6 (IL–6) (A), C-reactive
protein (CRP) (B) and Chlamydia pneumoniae IgG (C) levels
between the patients and controls. Box and whisker plot for
continuous variables in two groups. Circles represent outlier
values
There was a significant difference between the patients
and the controls regarding to CRP (Figure 1); 51% of the pa-
tients had CRP above the referent range as compared to 8%
of controls (χ
2 test, p < 0.001; OR, 11.97; 95% CI, 4.97 −
29.81).
The median of this marker of inflammation was 1.2
mg/dL (0.384 – 2.895) in the patients and 0.225 mg/dL
(0.075 – 0.623) in controls (Figure 2-B), (Mann-Whitney U
test, p < 0.001).
According to our results, there was a significant differ-
ence between the patients and the controls in regard to the
presence of Cp IgG antibodies: 72% of the patients were
positive versus 22% of the controls, (χ
 2 test p < 0.001; OR,
9.12; 95% CI, 4.57 – 18.35) (Figure 1).  IgG titers were sig-
nificantly higher in patients compared to the controls: 0.825
o.d. (0.669 – 1.00) vs 0.552 o.d. (0.410 – 0.705), (t-test,
p < 0.001) (Figure 2-C).
In an effort to examine, the inflammatory immune re-
actions concentrations of IL-6 and CRP were analyzed. Pear-
son’s linear correlation showed a correlation between IL - 6
and CRP (r = 0.454; p = 0.01).
Our data also showed a correlation between concentra-
tion of CRP and circulating Cp IgG antibodies, p = 0.01.We
did not find any correlation between circulating levels of IL-
6 and Cp IgG antibodies (Pearson’s linear correlation,
p=356).
Concentrations of IL–6 were higher in women
(p  =  0.03), patients with previous MI (p = 0.03),  previous
CABG (p = 0.03), smokers (p = 0.001), patients with hyper-
tension (p = 0.001) and with diabetes (p = 0.01) and corre-
lated with BMI (p = 0.01). Significant correlations were not
found between IL-6 levels and age (r = 0.185,  p = 0.081),
triglyceride levels (p =  0.09), total cholesterol levels
(p =  0.08), monocytes and WBC count (r  =  0.008,
p = 0.947), (Table 3).
In similar fashion, CRP was also higher in women
(p = 0.03), patients with previous history of MI (p = 0.03),
previous CABG (p = 0.03), smokers (p = 0.001), hyperten-
sive patients (p =  0.01) and patients with diabetes
(p = 0.05). Positive and significant relationships were dem-
onstrated between CRP levels and total cholesterol serum
levels (r = 0.333,  p =  0.01), with monocytes count
(p =  0.01) and BMI (p = 0.01).  Interestingly,  CRP  levels
were not significantly associated with serum triglyceride
levels (p =  0.085), with WBC count and age (r = 0.156,
p = 0.134) (Table 3).
Increasing WBC count was positively associated with
increasing titers of Cp IgG antibodies (r = 0.252, p = 0.05).
Even stronger association was noticed between the increas-
ing number of monocytes and increasing titers of Cp IgG an-
tibodies (r = 0.356, p = 0.01). Titers of Cp antibodies were
higher in smokers than in non-smokers (p = 0.001) (Table 4).
In an effort to examine the relationship between ECG
findings on admission and vascular inflammatory markers,
concentrations of IL-6 and CRP were analyzed in the sub-
groups of patients with or without ST-segment elevation.
There was a significant correlation regarding to severity of
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elevation had higher circulating levels of IL-6 (p = 0.03) and
CRP (p = 0.05). The high-risk ECG was followed by higher
concentrations of inflammatory markers.
Echocardiography was not essential early after myocar-
dial infarction, but was useful after MI to assess left ven-
tricular function. Left ventricle ejection fraction (LVEF) was
an important prognostic variable in the patients with ACS.
Both, IL-6 levels and CRP levels showed a strong and
significant correlation with LVEF (Pearson’s linear correla-
tion, r = -0.359, p = 0.01 for IL - 6 and r = -0.371, p = 0.01
for CRP) (Figure 3 and 4). However, there was no correla-
tion between Cp IgG antibodies titer and LVEF (r = -0.059,
p = 0.619).
Fig. 3 − Correlation between circulating interleukin 6 (IL-6)
and left ventricle ejection fraction (LVEF)
Fig. 4 − Correlation between high sensitive C- reactive pro-
tein (hs CRP) and left ventricular ejection fraction (LVEF)
Finally, to examine independent correlates of IL-6,
CRP and Cp IgG antibodies in prediction of a new event or
death in a follow-up period, adjustment analyzes were per-
formed by using binary logistic regression.  IL-6
(p = 0.007) and WBC count (p < 0.001) were strong inde-
pendent factors of death (Table 5). Kolmogorov Smirnov
test previously showed abnormal distribution of CRP.
Logarithmically normalized CRP showed positive but
weaker correlation (p = 0.035) as an independent predictor
of death.
Similarly, IL-6 was independently associated with new
coronary event (p = 0.013), as well as age (p < 0.001) (Table
6). There were no associations between CRP and new or re-
current MI or rehospitalization for ACS in 30-day of the
follow-up.
Table 3
Correlations of interleukin 6 (IL-6) and C-reactive protein (CRP)
with different parameters
IL-6 CRP
Parameters
pp
Age
Women
Hypertension
Diabetes
Total cholesterol
Triglycerides
Body mase index
Current smoker
Prior myocardial infarction
Prior coronary artery by pass grafting
White blood cell count
Monocytes
ST-elevation
0.081
0.03
0.001
0.01
0.08
0.09
0.01
0.001
0.03
0.03
0.947
0.964
0.03
0.134
0.03
0.01
0.05
0.01
0.085
0.01
0.001
0.03
0.03
0.134
0.01
0.05
Table 4
Correlations of Chlamydia pneumoniae IgG (Cp IgG)
with different parameters
Cp IgG
Parameters r p
White blood cells 0.252 0.05
Monocytes 0.359 0.001
Current smoker 0.368 0.001
Left ventricular ejection fraction - 0.371 0.619Volumen 65, Broj 6 VOJNOSANITETSKI PREGLED Strana 431
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Discussion
The aims of this study were to determine the possible
relationship between IL-6, CRP and Cp IgG antibodies in
patients presented with ACS-clinical manifestation of the
latter phase of atherothrombosis.
To our knowledge, these are the first reports of the previous
exposure to Cp pathogen and of an association with inflamma-
tory-immune markers in our patient population with ACS.
The results suggest that the high proportion of patients
had high titers of Cp IgG, high circulatory levels of both IL-6
and CRP, indicated the ongoing inflammation in ACS.
Our understanding of the pathogenesis of the acute
thrombotic complications of the arteriosclerosis has widen in
recent years. We now understand that many acute thrombotic
coronary occlusions do not necessarily result from critically
stenosed sites in the arteries. This distinction between lesions
versus lumen diameter challenges our traditional reliance
upon coronary anatomy. As in the initiation and progression
of arteriosclerosis, ample data support the involvement of in-
flammation in these thrombotic complications of arterioscle-
rosis 
10-13. The inflammatory stimuli produced by primary
proinflammatory cytokines may undergo amplification
through the induction of IL-6 production. Multiple cell types
including vascular smooth muscle cells, endothelial cells,
adipocytes can produce large amounts of IL-6.
A soluble mediator, IL-6, is a primary stimulant for the
hepatic acute phase response and the only cytokine capable
of inducing all acute phase proteins involved in the inflam-
matory response 
14.  As such, the induction of CRP by IL-6
underline atherogenesis. Similar to this finding, our data con-
firmed the correlation between CRP and IL-6.
C-reactive protein, an acute phase reactant and impor-
tant component of the innate immune system, has emerged as
not only a strong biomarker of vascular disease, but also as a
potential participant in it. Multiple prospective epidemiol-
ogical studies are focused on CRP that has been shown to
predict incident myocardial infarction, stroke and peripheral
arterial diseases. These highly consistent data are supported
by laboratory evidence demonstrating that atherothrombosis,
in addition to being a disease of lipid accumulation, repre-
sents a chronic inflammatory process 
15−18.
If we have a proof of ongoing inflammatory response in
the wounded coronary arteries there remains the question of
a trigger that might initiate and sustain the process. Among
“candidates” that could trigger both inflammatory and
autoimmune responses, there is infection 
19. Since the origi-
nal studies of Saikku et al. 
20 published in 1998, Cp bacteria
have been considered the main vascular pathogens increasing
the risk for CAD. Meta-analysis performed by Danesh et
al. 
21 in 2000 identified 15 prospective studies of Cp and
CAD. In our study Cp antibody titers were also elevated.  In
the present patient population, the proportion of subjects
with a high antibody response against Cp was 72%.  The
findings of Arnholm et al. 
22 are similar. The observed anti-
body responses for microbes in our study may reflect
chronic, but also reactivated latent infections. The findings of
Kark et al. 
23 and Sheehan et al. 
24 do not support an associa-
tion between specific antigen and ACS.
Chlamydia pneumoniae is responsible for a variety of
respiratory illnesses and can be distributed via monocytes
from respiratory tract to distant sites in the organism 
25.
Our study confirmed a correlation between monocytes and
Cp antibodies. In the same fashion there was a correlation
between WBC and Cp antibodies.
If an infected macrophage attaches to the vessel wall, it
may infect the cells lining the arterial surface and the artery
would then attract more immune cells. And, the vicious cir-
cle is triggered.
The host response to infectious agents usually involves
a change in the program of hepatic protein synthesis. The
cytokine IL-6 may mediate much of this switch from pro-
Table 5
Multivariate predictors (Logistic regression) of death in 111 patients
with acute coronary syndromes
95% CI for OR
OR p Lower bound Upper bound
Interleukin-6 1.084 0.007 1.023 1.149
White blood cells 0.629 0.000 0.488 0.809
Log hs CRP* 2.456 0.035 1.065 5.661
*log Hs CRP, logarithmically transformed high sensitivity C-reactive protein. Variables
entered in step 1: Chlamydia pneumoniae IgG antibodies, smoking status (including
current and ex-smokers, years of age, monocytes count, diabetes, previous myocardial
infarction, gender.
Table 6
Multivariate predictors (Logistic regression) of new event in
patients with acute coronary syndromes
95% CI for OR
OR p Lower bound Upper bound
Interleukin-6 1.059 0.013 1.012 1.108
Years of age 0.984 0.001 0.974 0.993
Variables entered in step 1: Chlamidia pneumoniae IgG antibodies, smoking
status (including current and ex-smokers), years of age, monocytes count, diabe-
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duction of ‘housekeeping proteins’ (such as albumin), to
greater synthesis of acute phase reactants. Our study demon-
strated a correlation between circulating titers and concen-
tration of CRP, indicating that degree of infection is followed
by inflammatory-immune response.
Major traditional risk factors of cardiovascular diseases
are smoking and diabetes and hypertension, obesity and
dyslipidemia. We found that cigarette smoking may be re-
lated to elevated levels of IL-6, CRP and Cp IgG antibodies.
The mechanism whereby smoking is related to concentra-
tions of IL-6, CRP and Cp is multifactorial and can be due to
bronchial injury, endothelial activation and systemic in-
flammation, as described elsewhere 
26.
We demonstrated that several other risk factors to be re-
lated to levels of IL-6 and CRP - specifically, the presence of
hypertension, diabetes and BMI. Nowadays, this cluster of
cardiometabolic risk factors is known as metabolic syndrome
− a condition underlined by low grade systemic inflammation,
or condition with systemic proinflammatory burden 
27, 28.
 Inflammation tightly regulates the procoagulant poten-
tial of the arteriosclerotic plaque. Thus, in the setting of local
inflammation in the plaque or systemic inflammation as re-
flected by the acute-phase response, inflammatory pathways
conspire to promote thrombosis and combat fibrinolysis.
Consequently, inflammation promotes clot formation and in-
stability and underlines the thrombotic aspects of athero-
thrombosis, as well as the lesion initiation and progression 
29.
If the thrombi are large or occlusive they lead to the acute
coronary syndromes.
Our results showed that IL-6 and CRP concentrations
are higher in the patients presented with ACS with ST-
segment elevation compared to patients presented with ACS
without ST-segment elevation. Moreover, we found that
both, IL-6 and CRP concentration correlate with LVEF. Such
results suggest that the levels of inflammatory markers cor-
relate with the severity of a disease.
Importantly, IL - 6 and CRP concentrations, but not Cp
antibodies, predict future death in the group of patients with
ACS (confirmed by using multiple linear models). These
findings indicate that levels of CRP, IL - 6 and WBC are
markers of disease activity. In the same fashion, IL - 6 was
the best predictor of new cardiovascular event, manifested as
new MI or UA.
The finding that an elevated WBC count was associated
with a higher mortality rate is in agreement with previous
studies 
30, 31. The basis for this remains unknown. It is possi-
ble that WBC count is a cause or simply a consequence of
ACS and that the degree of elevation of WBC count reflects
the severity of a disease.
Conclusion
Our study indicated that IL-6, CRP and Cp antibodies
were connected with the development of ACS, severity of
diseases and might reflect the clinical outcome in our patient
population. Interleukin-6, CRP and Cp antibodies were also
associated with several traditional risk factors, supporting the
idea of separate or concurrent pathway towards atherothrom-
bosis and indicating the possibility of direct vascular effect
on plaque stability. Future studies should find out the exact
evidences of causes or consequences of arteriosclerotic coro-
nary artery disease.
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